SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:uu-110978"
 

Search: onr:"swepub:oai:DiVA.org:uu-110978" > Type I interferon a...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Rönnblom, LarsUppsala universitet,Institutionen för medicinska vetenskaper (author)

Type I interferon and lupus

  • Article/chapterEnglish2009

Publisher, publication year, extent ...

  • 2009
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-110978
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-110978URI
  • https://doi.org/10.1097/BOR.0b013e32832e089eDOI
  • https://res.slu.se/id/publ/27843URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:for swepub-publicationtype

Notes

  • PURPOSE OF REVIEW: Patients with lupus have signs of an ongoing production of type I interferons (IFNs) that are of importance both for the etiopathogenesis and the clinical manifestations. In this review, we summarize the latest information concerning the type I IFN system in lupus. RECENT FINDINGS: Activated plasmacytoid dendritic cells are responsible for the IFNalpha production in lupus and can be found in target organs such as glomeruli. The plasmacytoid dendritic cells are triggered by interferogenic immune complexes, and produced IFNalpha activates the immune system and impairs T-regulatory cell function. Autoantibodies, which can form interferogenic immune complexes, are not only present in serum of lupus patients but also in the cerebrospinal fluid of patients with neuropsychiatric manifestations. There is a strong association between risk to develop lupus and gene variants connected to the production and effects of type I IFN. Risk variants can not only cause either increased serum IFNalpha activity or sensitivity but also a more severe disease phenotype. Administration of monoclonal anti-IFNalpha antibodies to lupus patients downregulates several proinflammatory pathways and reduces disease activity. SUMMARY: Increasing evidence indicates that the activated type I IFN system in lupus is critical in the etiopathogenesis of the disease and is an important therapeutic target.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Alm, GunnarSwedish University of Agricultural Sciences,Sveriges lantbruksuniversitet,Inst för biomedicin och veterinär folkhälsovetenskap,Department of Biomedical Science and Veterinary Public Health(Swepub:slu)48141 (author)
  • Eloranta, Maija-LeenaUppsala universitet,Institutionen för medicinska vetenskaper(Swepub:uu)maelo020 (author)
  • Uppsala universitetInstitutionen för medicinska vetenskaper (creator_code:org_t)
  • Sveriges lantbruksuniversitet

Related titles

  • In:Current Opinion in Rheumatology21:5, s. 471-4771040-87111531-6963

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view